No Data
Express News | Guangxi Wuzhou Zhongheng Group: The wholly-owned subsidiary Zhongheng Yixin plans to invest 34 million yuan to establish a joint venture.
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary plans to participate in the establishment of FOSUN PHARMA (Nanning) Co., Ltd.
Gelonghui reported on December 27 that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that in order to meet the needs of the company's Business development, further expand the layout of the overseas market Business and enhance comprehensive competitiveness, Guangxi Wuzhou Zhongheng Group's wholly-owned subsidiary Zhongheng Yixin plans to establish a joint venture with the wholly-owned subsidiary of FOSUN PHARMA, Shanghai FOSUN PHARMA Industrial Development Co., Ltd. (referred to as "FOSUN Industrial Company"), and Nanning Industry Investment Unified Investment Group Co., Ltd. (referred to as "Unified Investment Group"). The registered capital of the joint venture is 100 million yuan, of which FOSUN Industrial Company contributes 5,100.
On December 27, FOSUN PHARMA (02196.HK) spent 2.8723 million Hong Kong dollars to repurchase 0.2045 million shares.
On December 27, Gelonghui reported that FOSUN PHARMA (02196.HK) announced the repurchase of 0.2045 million shares for HKD 2.8723 million on December 27, 2024, with a repurchase price of HKD 13.94-14.1 per share.
Express News | State Council meeting: Deploy measures to deepen the reform of Pharmaceutical and medical instruments regulatory system to promote high-quality development of the pharmaceutical industry.
FOSUN PHARMA (02196.HK): The prerequisites for the absorption merger with HENLIUS (02696.HK) have been met.
FOSUN PHARMA (02196.HK) announced that as of last Monday (the 16th), the preconditions for the implementation of the absorption merger and privatization Trade agreement for its holding subsidiary HENLIUS (02696.HK) have all been met, including approval, filing, or registration from the National Development and Reform Commission and Other relevant authorities. HENLIUS will hold an extraordinary Shareholder meeting and H股 class Shareholder meeting on January 22, 2025, to deliberate on the proposals related to this Trade.
Shanghai Fosun Pharmaceutical Subsidiary Signs Cooperation, License Deal
